AUTHORS
Ramon Massoni-Badosa, PhD, Levan Mekerishvili2, Abigail G Thress3, Chiara Tomasoni, PhD4, Barun Pradhan, PhD5, Rebecca M Murray6, Andrew Lipsky, MD7, Kai Beattie8, Ronan Chaligne, PhD9, Ekaterina Kim, MS, PhD10, Gitanjali Jayachandran, PhD11, Erica B Bhavsar, BS12, Stacey M. Fernandes, BS13, John N Allan, M.D.14, Jennifer R. Brown, MD, PhD15, Jan A. Burger, MD, PhD16, Richard R Furman, MD17, Dan Avi Landau, MD, PhD18, Elisa ten Hacken, PhD19
AFFILIATIONS
1 New York Genome Center, New York, New York, United States, Weill Cornell Medicine, New York, New York, United States
2 New York Genome Center, New York, New York, United States, Weill Cornell Medicine, New York, New York, United States
3 New York Genome Center, New York, New York, United States, Weill Cornell Medicine, New York, New York, United States
4 Weill Cornell Medicine, New York, New York, United States
5 New York Genome Center, New York, New York, United States, Weill Cornell Medicine, New York, New York, United States
6 New York Genome Center, New York, New York, United States, Weill Cornell Medicine, New York, New York, United States
7 Columbia University Medical Center, New York, New York, United States
8 New York Genome Center, New York, New York, United States, Weill Cornell Medicine, New York, New York, United States
9 Memorial Sloan Kettering Cancer Center, New York, New York, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 Weill Cornell Medicine, New York, New York, United States
13 Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States
14 Weill Cornell Medicine, New York, New York, United States
15 Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States
16 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
17 Weill Cornell Medicine, New York, New York, United States
18 New York Genome Center, New York, New York, United States, Weill Cornell Medicine, New York, New York, United States
19 Weill Cornell Medicine, New York, New York, United States
ABSTRACT
Mutations in the BTK kinase domain confer resistance to covalent (cBTKi) and non-covalent (ncBTKi) BTK inhibitors in chronic lymphocytic leukemia (CLL), and are classified by phosphorylation capacity as kinase-proficient (C481S), kinase-impaired (C481R/F/Y) or kinase-enhanced (T474I), the latter retaining phosphorylation capacity in the absence of B-cell receptor (BCR) stimulation. Yet, one-third of BTKi-resistant patients lack BTK mutations and, when present, these often remain subclonal, with wild-type (WT) cells expanding alongside mutant (MUT) clones, in defiance of classical clonal selection. What transcriptional states sustain these WT cells, and whether different BTK mutations underlie different cell states, remains unknown.
To build a genotype-resolved map of resistance-associated cell states, we applied genotyping of transcriptomes (GoT; simultaneous mutation calling and whole-transcriptome profiling in single cells) to 516,895 circulating CLL cells from 25 patients (16 male, 9 female) progressing on cBTKi (ibrutinib, n=14; acalabrutinib, n=6; zanubrutinib, n=2) or ncBTKi (pirtobrutinib, n=3). We profiled 37 samples, including a resistant sample for each patient, and 12 paired pre-treatment samples.
Guided by BTK targeted deep sequencing, we selected patients with ≥1 subclonal BTK mutation at resistance (VAF 3-61%), ensuring representation of both WT and MUT cells within the same sample. We genotyped 1-4 mutations per patient, including C481S/R/Y/F, T474I and L528W, with a WT or MUT genotype call obtained in 42.2% of cells (range 9.6–77.5% across patients).
We applied non-negative matrix factorization and clustered 189 robust, non-redundant factors across all samples into metaprograms (MPs), defined as recurrent intratumoral cell states shared across subsets of patients. We annotated MPs by testing their most recurrent genes (66-109/MP) for enrichment against curated gene sets of CLL, Richter Transformation (RT), physiological B-cell states, and B-cell-specific cytokine responses. Beyond the established CXCR4highCD5low (MP7) and CXCR4lowCD5high (MP6) states, we identified a "MYC-high CLL Proliferative-Drive (CLL-PD)" state (MP2), enriched for the following gene sets: CLL-PD (OXPHOS, MTOR, MYC targets), a recently reported MIR155HG-high cell state in RT, and B-cell IL-4 response (all FDR<0.001, FC>10), pointing to a cell-extrinsic driven state. We detected two additional cell-extrinsic states, "IFN-stimulated" (MP5; type I IFN-stimulated genes IFIT1, IFIT2, STAT1) and "CD229+ IFNγ-stimulated" (MP8; the CLL-associated antigen LY9/CD229, IFI30, BCL2), together with an NF-κB-high state (MP9; NFKB1, RELB, CD83, CD40). All these MPs mapped to normal states in B-cell maturation, including pre-germinal center/recycling centrocytes (MP2) and CD229+ naive B cells (MP8).
To test whether BTK inhibition led to contraction or expansion of these MPs, we interrogated a published longitudinal bulk RNA-seq cohort of 20 acalabrutinib-treated patients. All these MPs except MP7 decreased after one cycle of treatment (p<0.05), most markedly MP2 and MP9. In our GoT dataset, at least 100 MP2+ cells were present in 9/12 pre-treatment and 17/25 resistant samples, indicating that MP2 represents a pre-existing state suppressed by effective BTK inhibition and re-expanding at resistance, with cells converging onto it across different BTKi treatments and across kinase-impaired and kinase-proficient BTK-MUT and BTK-WT genotypes.
To link genotype to cell state, we compared MP scores and MP+ fractions between genotypes per patient. In 4/25 patients (16%), BTK-WT cells overexpressed MP5 and/or harbored a larger MP5+ fraction than MUT cells, suggesting that their potential survival and expansion at resistance occur through type I IFN signaling, a nonmutational mechanism. Consistently, 2 of these 4 harbored an additional cluster of CD229+ IFNγ-stimulated MP8+ cells. Finally, in 2/2 patients with subclonal kinase-enhanced T474I, including one with concomitant C481S, the MP9 score was higher in T474I than in WT or C481S-mutant cells, representing the first association of T474I with an NF-κB-high state in primary CLL samples.
Together, our genotype-resolved map of BTKi resistance-associated cell states in CLL reveals under-explored survival mechanisms in both BTK-MUT and BTK-WT cells and provides a framework to map resistance mutations to cell phenotypes in lymphoid neoplasms.
DISCLOSURES
Ramon Massoni-Badosa, PhD: No relevant conflicts of interest to declare.